AI-Powered Long COVID Research

Long COVID encompasses persistent symptoms lasting weeks to years after SARS-CoV-2 infection. AI agents research viral persistence, immune dysregulation, microclotting, and mitochondrial rescue strategies.

Standard of Care

No FDA-approved treatments. Symptom-directed management: pacing for fatigue, cardiac rehab for dysautonomia, cognitive rehabilitation, antihistamines for mast cell activation. NIH RECOVER initiative funding research.

Prevalence

~65 million people worldwide affected. ~16 million Americans report long COVID symptoms. Affects all age groups.

Key Biomarkers

• Spike protein persistence (monocytes)
• Microclots (fluorescence microscopy)
• Complement activation (C5a, sC5b-9)
• T-cell exhaustion markers (PD-1)
• Serotonin levels (reduced)

Emerging Research

Metformin reduced long COVID incidence by 41% in the COVID-OUT trial when given early. Triple anticoagulant therapy targeting microclots (Pretorius protocol). Paxlovid for viral persistence hypothesis. Stellate ganglion block for dysautonomia. Low-dose naltrexone for neuroinflammation. Apheresis trials for spike protein clearance.

Frequently Asked Questions

What causes long COVID?

Four leading hypotheses: (1) viral persistence in tissue reservoirs, (2) autoimmunity triggered by molecular mimicry, (3) microclotting and endothelial dysfunction, (4) gut dysbiosis with reduced serotonin production. These mechanisms likely overlap and vary between patients.

Can metformin prevent long COVID?

The COVID-OUT trial showed metformin reduced long COVID incidence by 41% when started within 3 days of symptom onset. The mechanism may involve anti-inflammatory effects, viral replication inhibition, and metabolic protection. This is one of the strongest preventive interventions identified to date.

What are microclots in long COVID?

Amyloid fibrin microclots — abnormally resistant to fibrinolysis — have been found in long COVID patients' blood. These may impair capillary blood flow and oxygen delivery, explaining fatigue and cognitive symptoms. Anticoagulant and fibrinolytic protocols are being studied.